Details of the Drug Combinations

General Information of This Drug (ID: DMOLNHF)

Drug Name

Melphalan DMOLNHF

Synonyms

Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine

Indication

Disease Entry	ICD 11	Status	REF
Hematologic disease	3C0Z	Approved	[1]
Leukemia	N.A.	Approved	[1]
Multiple myeloma	2A83	Approved	[2]
Myeloproliferative neoplasm	2A20	Approved	[1]
Ovarian cancer	2C73	Approved	[3]
Plasma cell myeloma	2A83.1	Approved	[1]
Refractory plasma cell neoplasm	N.A.	Approved	[1]
Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[5]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]
Retinoblastoma	2D02.2	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Melphalan + Idarubicin	DCXY3MW	Idarubicin	Glioblastoma? (Cell Line: T98G)	[6]
------------------------------------------------------------------------------------

6 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Melphalan + Fludarabine	DCOSRRA	Fludarabine	Accelerated Phase Chronic Myelogenous Leukemia	[7]
Mycophenolate mofetil + Melphalan	DC4ODJA	Mycophenolate mofetil	Refractory Multiple Myeloma	[8]
Mycophenolate mofetil + Melphalan	DCINNR2	Mycophenolate mofetil	Refractory Multiple Myeloma	[9]
Thiotepa + Melphalan	DCL1TVN	Thiotepa	Hematologic Malignancies	[10]
Etoposide + Melphalan	DCSAF8Y	Etoposide	Lymphoma	[11]
Sirolimus + Melphalan	DCEOXNJ	Sirolimus	Graft Versus Host Disease	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

References

1	Melphalan FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7620).
3	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201379.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	ClinicalTrials.gov (NCT04380376) Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia. U.S. National Institutes of Health.
6	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
7	ClinicalTrials.gov (NCT00856388) Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
8	ClinicalTrials.gov (NCT00054353) Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
9	ClinicalTrials.gov (NCT00003954) Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
10	ClinicalTrials.gov (NCT01350258) Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
11	ClinicalTrials.gov (NCT00695409) Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
12	ClinicalTrials.gov (NCT00577278) A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan